Evaluation of Prognostic Monitoring for Women Who Have Completed Standard Treatment for Breast Cancer

2019 ◽  
Author(s):  
Keyword(s):  
Breast Cancer ◽  
Standard Treatment

Surgical Clips in Breast-conserving Surgery: Do they Represent the Tumour Bed Accurately?

2019 ◽  
Vol 15 (6) ◽  
pp. 573-577
Author(s):  
Ozlem Demircioglu ◽  
Erkin Aribal ◽  
Meral Uluer ◽  
Zerrin Ozgen ◽  
Fatih Demircioglu
Keyword(s):  
Breast Cancer ◽  
Standard Treatment ◽  
Breast Conserving Surgery ◽  
Radiotherapy Planning ◽  
Surgical Scar ◽  
Surgical Clips ◽  
End Of Treatment

Introduction: Radiotherapy after Breast-Conserving Surgery (BCS) is a standard treatment for breast cancer. Currently, surgical clips are used to determine the tumour bed before radiotherapy planning. This study aimed to evaluate the migration of these clips on mammograms. Methods: The study was conducted on 121 females who were treated with radiotherapy after BCS at their first radiologic control examination 6 months after the end of treatment. MLO and CC views of all cases were evaluated regarding the clips. The distance between the surgical scar centre and the centre of the area covered by the clips was measured on both MLO and CC projections and recorded separately. This distance was determined as the clip displacement. A displacement ≤10 mm was recorded as no displacement. Results: The clips were out of the images and were not evaluated in 45 cases (37.2%) on CC and in 9 cases (7.4%) on MLO projections. There were no clip displacements in 37 (30.6%) cases on CC and in 43 (35.5%) cases on MLO views. The amount of displacement ranged from 11 to 56 mm with a mean of 24.38 mm on CC views, while on MLO projections, displacement ranged from 11 to 66 mm with a mean of 24.42 mm. Conclusion: A clip displacement of greater than 10 mm was found in 64.5% of cases on MLO views. Therefore, we believe that the reliability of these clips for accurate delineation of the tumour bed in radiotherapy planning is controversial and other methods must be added.

scholarly journals Nuclear Mechanisms Involved in Endocrine Resistance

2021 ◽  
Vol 11 ◽  
Author(s):  
Jürgen Dittmer
Keyword(s):  
Breast Cancer ◽  
Estrogen Receptor ◽  
Endocrine Therapy ◽  
Standard Treatment ◽  
Current Knowledge ◽  
Endocrine Resistance ◽  
Estrogen Receptor Α ◽  
Cyclin Dependent Kinase ◽  
Druggable Targets ◽  
Positive Breast Cancer

Endocrine therapy is a standard treatment offered to patients with ERα (estrogen receptor α)-positive breast cancer. In endocrine therapy, ERα is either directly targeted by anti-estrogens or indirectly by aromatase inhibitors which cause estrogen deficiency. Resistance to these drugs (endocrine resistance) compromises the efficiency of this treatment and requires additional measures. Endocrine resistance is often caused by deregulation of the PI3K/AKT/mTOR pathway and/or cyclin-dependent kinase 4 and 6 activities allowing inhibitors of these factors to be used clinically to counteract endocrine resistance. The nuclear mechanisms involved in endocrine resistance are beginning to emerge. Exploring these mechanisms may reveal additional druggable targets, which could help to further improve patients’ outcome in an endocrine resistance setting. This review intends to summarize our current knowledge on the nuclear mechanisms linked to endocrine resistance.

scholarly journals Bronchoalveolar carcinoma as an unsuspected cause for worsening shortness of breath in a patient with metastatic breast cancer

2018 ◽  
pp. bcr-2018-226125
Author(s):  
Sukhdeep Kaur Nagpal ◽  
Michael Flynn ◽  
Claire Ryan ◽  
Catherine Harper-Wynne
Keyword(s):  
Breast Cancer ◽  
Metastatic Breast Cancer ◽  
Standard Treatment ◽  
Lung Metastases ◽  
Metastatic Breast ◽  
Multimodality Treatment ◽  
Chest Ct ◽  
Postmortem Examination ◽  
Shortness Of Breath ◽  
Radiological Changes

A 70-year-old woman with lung metastases from a breast cancer presented with worsening cough and dyspnoea. She recently had a pleurodesis for a malignant pleural effusion. Chest CT scans demonstrated various radiological changes leading to diagnostic challenges. Differential diagnoses included empyema, pleural disease progression, pulmonary oedema, pneumonitis, lymphangitis and atypical infections. She deteriorated despite a multimodality treatment strategy. Postmortem examination confirmed that lung changes were consistent with a bronchoalveolar carcinoma unrelated to the known metastatic breast cancer. The eventual knowledge of this diagnosis was reassuring to the treating medical team and a comfort to the relatives who witnessed the lack of response to standard treatment.

Standard treatment in very old breast cancer patients. Recommended or not recommended?

2020 ◽  
Vol 138 ◽  
pp. S109
Author(s):  
M. Bortolini ◽  
L. Idda ◽  
D. Bono ◽  
E. Trino ◽  
R. Ragona ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Cancer Patients ◽  
Standard Treatment ◽  
Breast Cancer Patients ◽  
Very Old

Effect of additional administration of pertuzumab for the post-treatment in patients with HER2-positive locally advanced/metastatic breast cancer who were previously treated with pertuzumab.

2019 ◽  
Vol 37 (15_suppl) ◽  
pp. e12500-e12500
Author(s):  
Shinichiro Kubo
Keyword(s):  
Breast Cancer ◽  
Metastatic Breast Cancer ◽  
Anticancer Agents ◽  
Clinical Benefit ◽  
Standard Treatment ◽  
Locally Advanced ◽  
Metastatic Breast ◽  
Her2 Positive ◽  
Intervention Treatment ◽  
Previously Treated

e12500 Background: Currently, there are no data related to re-administering trastuzumab (T) + pertuzumab (P) beyond the second-line therapy to patients with human epidermal growth factor receptor 2-positive advanced/metastatic breast cancer (HER2-MBC) who had previously received P. The present study targeted patients with HER2-MBC who were previously treated with P and aimed to evaluate the efficacy and safety of additional administration (top-up intervention) of P post-disease progression (PD) after standard treatment with T plus chemotherapy vinorerbine(VNR) or eribulin (ERI). Methods: SBP-08 was a multicenter, collaborative, single-arm phase II study of HER2-MBC patients who had previously received P. After standard treatment with T and chemotherapy, P was additionally administered (top-up intervention) post-PD. Results: Eleven HER2-MBC patients, recruited between June 2016 and June 2018, who had previously received P participated in this study. Their mean age was 63.5 years, and 45% were estrogen receptor (ER)-negative, while 55% were ER-positive. The mean chemotherapy history was 3.6 regimens, with a median of four regimens. Previous treatment regimens with P had been effective in all patients. All patients had organ metastasis and treatment histories with TDM-1. Initially, during the two-year case collection period, registration of 30 patients was planned. However, the study was terminated because the interim analysis did not demonstrative effectiveness, and it was decided that there were no potential benefits to the patients. The overall response rate (ORR) of the standard treatment was 0%, stable disease (SD) was 36%, PD was 55%, and the clinical benefit rate (CBR) was 0%. The following combination anticancer agents were used: VNR (10 patients) and ERI (one patient). The intervention treatment (top-up with P) achieved the following: ORR 0%, SD 22%, PD 78%, and CBR 0%. PFS for the standard treatment was 1.6 months, whereas PFS for the intervention treatment was 1.3 months. In the standard treatment, febrile neutropenia was observed in two patients. No increases in adverse events were observed with the intervention treatment. Conclusions: No clinical benefit was demonstrated with the intervention treatment in the present study. Top-up with P after standard treatment with T and chemotherapy post-PD was deemed ineffective. Clinical trial information: UMIN000020837.

scholarly journals Future prospects for breast cancer immunotherapy

2018 ◽  
pp. 12-16
Author(s):  
V. F. Semiglazov ◽  
A. I. Tseluiko ◽  
R. V. Donskikh ◽  
P. V. Krivorotko ◽  
G. A. Dashyan ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Cell Death ◽  
Monoclonal Antibodies ◽  
Surgical Treatment ◽  
Programmed Cell Death ◽  
T Lymphocyte ◽  
Standard Treatment ◽  
Immune Checkpoints ◽  
Future Prospects ◽  
Programmed Cell Death 1

Immunotherapy has already become an important component of the standard treatment of patients with advanced cancer. Most treatment methods include monoclonal antibodies (mAbs) that block immune checkpoints, in particular, the programmed cell death 1 (PD-1) receptor and its ligand 1 (PD-L1) or are directed against T-lymphocyte-associated protein 4 (CTLA-4). The future prospects for immuno-oncology will be to determine whether these agents can be more effective if administered in a postoperative adjuvant or in a neoadjuvant regimen prior to surgical treatment. Vaccine therapy has shown promising results, and this therapy is especially attractive due to absence of pronounced toxicity.

scholarly journals CRYOGENIC TECHNOLOGY IN MINIMALLY INVASIVE TREATMENT OF BREAST CANCER. LITERATURE REVIEW

2020 ◽  
Vol 66 (2) ◽  
pp. 103-108
Author(s):  
Aleksey Belyaev ◽  
Georgiy Prokhorov ◽  
Viktoriya Zakharova
Keyword(s):  
Breast Cancer ◽  
Literature Review ◽  
Minimally Invasive ◽  
Standard Treatment ◽  
Invasive Treatment ◽  
Scientific Validity ◽  
Control Material ◽  
Cryogenic Technology ◽  
Navigation And Control ◽  
And Control

The survey of literature includes period from the first attempts of palliative cryodestruction to modern miniinvasive technologies with the use of different methods of navigation and control. Material, that shows scientific validity, efficiency, positive technologic and clinical evolution of method, is collected sufficiently. But despite of general positive and optimistic assessment of cryogenic technologies’ opportunity, there are no results of randomized studies comparing distant results of cryogenic and existing standard treatment of breast cancer. In conclusion authors indicate the objective difficulties in problem’s studying and offer possible resolutions.

scholarly journals Successful Local Control With High-dose Palliative Radiation Therapy for Local Advanced Breast Cancer of Mucinous Carcinoma With Malignant Wound.

2021 ◽  
Author(s):  
Yojiro Ishikawa ◽  
Rei Umezawa ◽  
Takaya Yamamoto ◽  
Noriyoshi Takahashi ◽  
Kazuya Takeda ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Advanced Breast Cancer ◽  
Standard Treatment ◽  
Mucinous Carcinoma ◽  
Advanced Breast ◽  
High Dose ◽  
The Right ◽  
To Receive ◽  
Local Advanced ◽  
Local Advanced Breast Cancer

Abstract Background: Patients with breast cancer who refuse standard treatment often suffer from malignant wounds due to the growth of local tumors. However, treatment strategies for patients with unresectable locally advanced breast cancer who have refused standard treatment have been unclear.Case presentation: A 44-year-old female was diagnosed with breast cancer of mucinous carcinoma in the right breast. She refused standard treatment for her breast cancer for six years. She suddenly visited the emergency department because of acute bleeding from the right breast cancer with malignant wounds. Macroscopically, the tumor in the right breast measured over 20 cm in diameter. The tumor was exudative, exhibited ulceration and slight bleeding, and gave off an odor. Imaging findings showed multiple lymph node and bone metastases, and the final diagnosis was breast cancer of stage IV (cT4bN1M1). Although the surgeon recommended chemotherapy for the breast cancer, the patient refused to receive chemotherapy or other therapy due to concerns about complications during treatment. Considering the symptoms of advanced breast cancer with malignant wounds, she finally agreed to receive radiation therapy (RT). We performed RT of 70 Gy in 35 fractions over a period of 7 weeks. The tumor-associated symptoms were disappeared after RT. At three months after RT, the tumor had almost disappeared. We administered luteinizing hormone-releasing hormone agonists after RT. At two years after RT, she died due to multiple liver metastases and appearance of ascites; however, there was no disease progression in the right breast.Conclusions: High-dose RT for local advanced breast cancer of MC with malignant wounds is therefore considered to be an effective therapeutic option.

Sign in / Sign up

Export Citation Format

Share Document